Identifying Novel Targets for Enhancing Anti-PD1 Immunotherapy in Melanoma
DOI:
https://doi.org/10.54097/8jf4fp30Keywords:
Melanoma, Anti-PD1/PD-L1 treatment, FGFR signals, B cell infiltration.Abstract
Checkpoint inhibitors targeting PD-1/PD-L1 have become prominent treatments for advanced melanoma. However, these inhibitors are effective in less than half of patients, highlighting the need for new pathways and strategies to improve response rates. Analysis of RNA sequencing data from melanoma patients receiving anti-PD1/PD-L1 therapy revealed an enrichment of FGFR signaling in nonresponders, which was associated with a poorer prognosis. Additionally, it was found that FGFR signaling is negatively correlated with B cell signaling in melanoma tumors. Conversely, B cell receptor signaling is enriched in responders' tumors and associated with a better prognosis. This suggests that inhibiting FGFR or increasing the activation of B cells may be novel therapeutic targets for melanoma patients and aid in checkpoint inhibitor therapy. Further validation is necessary to assess the impacts on anti-PD1/PD-L1 therapy response. Overall, characterizing distinguishable pathways between responders and nonresponders may lead to more personalized immunotherapy selections and improved clinical outcomes for advanced melanoma.
Downloads
References
"Survival Rates for Melanoma Skin Cancer." American Cancer Society. https://www.cancer.org/cancer/types/melanoma-skin-cancer/detection-diagnosis-staging/survival-rates-for-melanoma-skin-cancer-by-stage.html (accessed July 25, 2023).
J.-Y. Sun et al., "Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives," Biomarker Research, vol. 8, no. 1, pp. 1-10, 2020.
T. García-Salum et al., "Molecular signatures associated with tumor-specific immune response in melanoma patients treated with dendritic cell-based immunotherapy," Oncotarget, vol. 9, no. 24, p. 17014, 2018.
W. Hugo et al., "Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma," Cell, vol. 165, no. 1, pp. 35-44, 2016.
M. Lauss et al., "Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma," Nature communications, vol. 8, no. 1, p. 1738, 2017.
E. M. Van Allen et al., "Genomic correlates of response to CTLA-4 blockade in metastatic melanoma," Science, vol. 350, no. 6257, pp. 207-211, 2015.
N. Riaz et al., "Tumor and microenvironment evolution during immunotherapy with nivolumab," Cell, vol. 171, no. 4, pp. 934-949. e16, 2017.
T. Li et al., "TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells," Cancer research, vol. 77, no. 21, pp. e108-e110, 2017.
A. Subramanian et al., "Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles," Proceedings of the National Academy of Sciences, vol. 102, no. 43, pp. 15545-15550, 2005.
R.-J. Bleichrodt and N. D. Read, "Flow cytometry and FACS applied to filamentous fungi," Fungal Biology Reviews, vol. 33, no. 1, pp. 1-15, 2019.
F. Rapaport et al., "Comprehensive evaluation of differential gene expression analysis methods for RNA-seq data," Genome biology, vol. 14, no. 9, pp. 1-13, 2013.
M. Czyz, "Fibroblast growth factor receptor signaling in skin cancers," Cells, vol. 8, no. 6, p. 540, 2019.
K. Suyama, I. Shapiro, M. Guttman, and R. B. Hazan, "A signaling pathway leading to metastasis is controlled by N-cadherin and the FGF receptor," Cancer cell, vol. 2, no. 4, pp. 301-314, 2002.
Y. Wang and D. Becker, "Antisense targeting of basic fibroblast growth factor and dibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth," Nature medicine, vol. 3, no. 8, pp. 887-893, 1997.
O. Straume and L. A. Akslen, "Importance of vascular phenotype by basic fibroblast growth factor, and influence of the angiogenic factors basic fibroblast growth factor/fibroblast growth factor receptor-1 and ephrin-A1/EphA2 on melanoma progression," The American journal of pathology, vol. 160, no. 3, pp. 1009-1019, 2002.
J. Grimm et al., "BRAF inhibition causes resilience of melanoma cell lines by inducing the secretion of FGF1," Oncogenesis, vol. 7, no. 9, p. 71, 2018.
M. Czyz, "HGF/c-MET Signaling in Melanocytes and Melanoma," International journal of molecular sciences, vol. 19, no. 12, p. 3844, 2018.
C. Y. Shiang et al., "Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate," Breast cancer research and treatment, vol. 123, pp. 747-755, 2010.
F. André et al., "Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer," Clinical cancer research, vol. 19, no. 13, pp. 3693-3702, 2013.
A. Ladányi, "Prognostic and predictive significance of immune cells infiltrating cutaneous melanoma," Pigment cell & melanoma research, vol. 28, no. 5, pp. 490-500, 2015.
L. Saul et al., "IgG subclass switching and clonal expansion in cutaneous melanoma and normal skin," Scientific Reports, vol. 6, no. 1, p. 29736, 2016.
B. A. Helmink et al., "B cells and tertiary lymphoid structures promote immunotherapy response," Nature, vol. 577, no. 7791, pp. 549-555, 2020.
Z. N. Willsmore et al., "B cells in patients with melanoma: implications for treatment with checkpoint inhibitor antibodies," Frontiers in Immunology, vol. 11, p. 622442, 2021.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
